Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 11/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA6 | P23280 | 1/20 | 0.33 |
| ▸ | CA5A | P35218 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3240959 | 0.80 | ADRB2 (0.44) | ADRB2GAAGLAPOLBTSHR | |
| SCHEMBL7520401 | 0.80 | CYP3A4 (0.36) | ADRB2GAAGLAPOLBTSHR | |
| SCHEMBL1639812 | 0.78 | GAA (0.58) | GAAMAPTTSHRCA1CA2 | |
| SCHEMBL2438192 | 0.77 | GAA (0.59) | ADRB2GAAMAPTGLAPOLB | |
| SCHEMBL9955892 | 0.77 | ADRB2 (0.42) | ADRB2GAAMAPTGLAPOLB | |
| SCHEMBL31580025 | 0.77 | EPAS1 (0.33) | EPAS1PDK2 | |
| SCHEMBL12069198 | 0.77 | GLA (0.33) | ADRB2GAAGLAPOLBTSHR | |
| SCHEMBL20973548 | 0.77 | ERN1 (0.46) | TSHRCA1CA2EPAS1PDK2 | |
| SCHEMBL980843 | 0.77 | GLA (0.33) | ADRB2GAAGLAPOLBTSHR | |
| SCHEMBL18007552 | 0.77 | ALDH1A1 (0.37) | ADRB2GAAMAPTGLAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4680607-A1 | BICYCLIC UREAS AS KINASE INHIBITORS | Incyte Corporation (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20250304582-A1 | Bicyclic Ureas As Kinase Inhibitors | INCYTE CORPORATION | 2025-10-02 | — | — | US | disclosed |
| WO-2025104443-A1 | INHIBITORY COMPOUNDS | STORM THERAPEUTICS LTD (GB) | 2025-05-22 | — | — | WO | disclosed |
| US-20240400502-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | UNIV QUEENSLAND (AU) | 2024-12-05 | — | — | US | disclosed |
| US-20240317744-A1 | Bicyclic Ureas As Kinase Inhibitors | INCYTE CORPORATION | 2024-09-26 | — | — | US | disclosed |
| CN-113582889-B | Sulfonylureas and related compounds and uses thereof | 昆士兰大学 | 2024-09-20 | — | — | CN | disclosed |
| WO-2024191996-A1 | BICYCLIC UREAS AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2024-09-19 | — | — | WO | disclosed |
| US-11845715-B2 | — | — | 2023-12-19 | — | — | US | disclosed |
| US-11845715-B2 | — | — | 2023-12-19 | — | — | US | disclosed |
| US-11845715-B2 | — | — | 2023-12-19 | — | — | US | disclosed |
| WO-2019079119-A1 | SULPHONAMIDES AND COMPOSITIONS THEREOF FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | IFM Tre, Inc. (US) | 2019-04-25 | — | — | WO | disclosed |
| US-20180044287-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | INFLAZOME LIMITED (IE) | 2018-02-15 | — | — | US | disclosed |
| US-20180044287-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | INFLAZOME LIMITED (IE) | 2018-02-15 | — | — | US | disclosed |
| EP-3259253-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | The University of Queensland (AU) | 2017-12-27 | — | — | EP | disclosed |
| WO-2017184604-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | IFM THERAPEUTICS, INC (US) | 2017-10-26 | — | — | WO | disclosed |
| WO-2017184604-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | IFM THERAPEUTICS, INC (US) | 2017-10-26 | — | — | WO | disclosed |
| WO-2016131098-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | THE UNIVERSITY OF QUEENSLAND (AU) | 2016-08-25 | — | — | WO | disclosed |
| WO-2016131098-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | THE UNIVERSITY OF QUEENSLAND (AU) | 2016-08-25 | — | — | WO | disclosed |
| US-20120053148-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES, INC. (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053148-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES, INC. (US) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11845715-B2 | — | NLRP3, PYCARD, NOD1 | ADRB2 4168/4885GAA 1190/4885MAPT 1265/4885 |
| US-20120053148-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, FABP1, EIF2AK2 | ADRB2 4590/4885GAA 456/4885MAPT 4071/4885 |
| US-20250304582-A1 | Bicyclic Ureas As Kinase Inhibitors | JAK2, UCK2, ULK2 | ADRB2 4431/4885GAA 3961/4885MAPT 2874/4885 |
| US-20240400502-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | NLRP3, PYCARD, IAPP | ADRB2 3836/4885GAA 706/4885MAPT 1672/4885 |
| US-20240317744-A1 | Bicyclic Ureas As Kinase Inhibitors | JAK2, UCK2, ULK2 | ADRB2 4431/4885GAA 3961/4885MAPT 2874/4885 |
| US-20180044287-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | NLRP3, PYCARD, IAPP | ADRB2 3836/4885GAA 706/4885MAPT 1672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.